In the Lab By Jonathan Wosen Scientists take key step toward unraveling the genetic roots of ALS in a pair of studies
Health By Elizabeth Cooney Long after the fire of a Covid-19 infection, mental and neurological effects can still smolder
Health By JoNel Aleccia — Kaiser Health News Worries about accuracy of widely used dementia test prompt training requirement
First Opinion By Bernard Zipprich Will the shadow of Aduhelm cloud FDA’s decision-making on an ALS therapy?
The Pharmalot View By Ed Silverman ‘Precedents are important’: Aduhelm coverage restrictions could shape the future of accelerated approval
Health Tech By Katie Palmer With pharma still struggling in Alzheimer’s, health tech companies want a swing
In the Lab By Meghana Keshavan With new ‘brain-reading’ research, a once-tarnished scientist seeks redemption
Video Chat By Gideon Gil Virtual Event – ‘Augmented’: The future of brain-controlled prosthetic limbs
Special Report By Isabella Cueto Jolting the brain’s circuits with electricity is moving from radical to almost mainstream therapy. Some crucial hurdles remain
Pharmalot By Ed Silverman A looming decision on Medicare coverage for Biogen’s Alzheimer’s drug could shock state Medicaid programs
Exclusive By Kate Sheridan Flagship to launch a new startup focused on neurodegenerative conditions, including Parkinson’s
Biotech By Matthew Herper Acadia drug meets endpoints for treating Rett syndrome, a rare neurological disease
Biotech By Damian Garde Cortexyme bets a lower dose of its once-failed Alzheimer’s drug can work in another trial
The Pharmalot View By Ed Silverman ‘Remember her as the badass she was’: ALS patient who died should force Biogen, others to anticipate expanded access issues
Pharmalot By Ed Silverman and Damian Garde Veterans Affairs declines to cover Biogen’s Alzheimer’s drug over effectiveness, safety concerns
Biotech By Joanne Silberner Accelerated approval, the path used to greenlight Biogen Alzheimer’s drug, has a checkered track record, critics say
Pharmalot By Ed Silverman Expert panel votes unanimously that Biogen Alzheimer’s drug doesn’t offer patient benefits
STAT Summit By Elizabeth Cooney ‘Aduhelm left room’: Lilly CEO eyes competition with Biogen Alzheimer’s drug
Pharmalot By Ed Silverman Poll: Most neurologists and primary care doctors disagree with FDA’s approval of Alzheimer’s drug
Pharmalot By Ed Silverman Will FDA quickly review a Lilly drug to alleviate cost concerns for Alzheimer’s treatments?
Health By Megan Molteni A crucial, overlooked question on the new Alzheimer’s drug: When should patients stop taking it?
Pharmalot By Ed Silverman Poll: Most Americans believe new Alzheimer’s drug is effective, but many are concerned with FDA process
Pharmalot By Ed Silverman ‘A litany of flaws’: Advocacy group urges HHS to boot FDA officials over Alzheimer’s drug approval
Health By Elizabeth Cooney ‘I’m just winging it’: Faced with confusing data on the new Alzheimer’s drug, doctors scramble to advise their patients
Biotech By Felice J. Freyer — Boston Globe What’s next for the new Alzheimer’s drug? Lots of thorny issues ahead